RecruitingPhase 1NCT07600788
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.
Sponsor
Ausper Biopharma Co., Ltd.
Enrollment
32 participants
Start Date
Jul 9, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called AHB-137 injection for people with chronic hepatitis b. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years to 65 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAHB-137 injection
Single use subcutaneous injection
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07600788
Related Trials
A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B
NCT07635186
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
NCT070695691 location
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
NCT028637571 location
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
NCT071461002 locations
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
NCT060923331 location